Trends in Immunotherapy

Communication

Association of anticardiolipin antibodies with epilepsy in children

Downloads

https://doi.org/10.24294/ti.v7.i1.2021
Shiva, S., Khanzadeh, S., Rashidi, F., & Lucke-Wold, B. (2023). Association of anticardiolipin antibodies with epilepsy in children. Trends in Immunotherapy, 7(1). https://doi.org/10.24294/ti.v7.i1.2021
Volume 7 Issue 1 (2023)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Shadi Shiva Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz 51368, Iran
  • Shokoufeh Khanzadeh Tabriz University of Medical Sciences, Tabriz 51368, Iran
  • Farzad Rashidi Tabriz University of Medical Sciences, Tabriz 51368, Iran
  • Brandon Lucke-Wold
    Department of Neurosurgery, University of Florida, Gainesville, FL 32611, United States

We investigated the association of anticardiolipin antibodies (aCL) with epilepsy development and characteristics in children. This prospective case-control study included 40 epileptic children and 40 sex- and age-matched controls. Epileptic children had higher levels of aCL compared to healthy controls (5.66 ± 5.41 versus 2.37 ± 2.28; p value = 0.001). The novel finding of elevated levels of aCL predicted response to IVIg therapy (p value = 0.009). Patients with normal EEG had lower levels of aCL compared to those with EEG abnormal findings (p value = 0.015). Patients with the combined type of epilepsy had statistically significant higher levels of aCL compared to other types (p value = 0.046). Also, aCL levels were correlated with seizure frequency (p value = 0.019). These results declare the possible involvement of such antibodies in the onset or pathogenesis of epilepsy. Screening for aCL may help in the timely diagnosis of epilepsy and initiation of appropriate treatment.

Keywords:

Epilepsy Anticardiolipin Antibody Antiphospholipid Antibody IVIG Children Seizure

References

  1. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia 2014; 55(4): 475–482. doi: 10.1111/epi.12550.
  2. Ong M-S, Kohane IS, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurology 2014; 71(5): 569–574. doi: 10.1001/jamaneurol.2014.188.
  3. Greco A, Rizzo MI, De Virgilio A, et al. Autoimmune epilepsy. Autoimmunity Reviews 2016; 15(3): 221–225. doi: 10.1016/j.autrev.2015.11.007.
  4. Thurman DJ, Logroscino G, Beghi E, et al. The burden of premature mortality of epilepsy in high-income countries: A systematic review from the mortality task force of the international league against epilepsy. Epilepsia 2017; 58(1): 17–26. doi: 10.1111/epi.13604.
  5. Chang BS, Lowenstein DH. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury: Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2003; 60(1): 10–16. doi: 10.1212/01.wnl.0000031432.05543.14.
  6. Duncan JS, Sander JW, Sisodiya SM, et al. Adult epilepsy. The Lancet 2006; 367(9516): 1087–1100. doi: 10.1016/S0140-6736(06)68477-8.
  7. Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of new international antiphospholipid syndrome classification criteria phase I/II report: Generation and reduction of candidate criteria. Arthritis Care & Research 2021; 73(10): 1490–1501. doi: 10.1002/acr.24520.
  8. Shoenfeld Y, Twig G, Katz U, et al. Autoantibody explosion in antiphospholipid syndrome. Journal of Autoimmunity 2008; 30(1–2): 74–83. doi: 10.1016/j.jaut.2007.11.011.
  9. Eriksson K, Peltola J, Keränen T, et al. High prevalence of antiphospholipid antibodies in children with epilepsy: A controlled study of 50 cases. Epilepsy Research 2001; 46(2): 129–137. doi: 10.1016/s0920-1211(01)00273-x.
  10. Verrotti A, Greco R, Altobelli E, et al. Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients. Clinical and Experimental Medicine 2003; 3(1): 32–36. doi: 10.1007/s102380300013.
  11. Liimatainen S, Peltola M, Fallah M, et al. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. European Journal of Neurology 2009; 16(1): 134–141. doi: 10.1111/j.1468-1331.2008.02373.x.
  12. Debourdeau P, Gérome P, Zammit C, et al. Frequency of anticardiolipin, antinuclear and anti β2GP1 antibodies is not increased in unselected epileptic patients: A case-control study. Seizure 2004; 13(4): 205–207. doi: 10.1016/S1059-1311(03)00112-2.
  13. Markić J, Meštrović M, Valić I, et al. Frequency of anticardiolipin, antinuclear and anti-β2 glycoprotein I antibodies in children with epilepsy. Collegium Antropologicum 2007; 31(3): 739–742.
  14. Veri K, Uibo O, Talvik T, et al. Newly-diagnosed pediatric epilepsy is associated with elevated autoantibodies to glutamic acid decarboxylase but not cardiolipin. Epilepsy Research 2013; 105(1–2): 86–91. doi: 10.1016/j.eplepsyres.2013.02.009.
  15. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58(4): 512–521. doi: 10.1111/epi.13709.
  16. Barkovich A, Berkovic S, Cascino G, et al. Recommendations for neuroimaging of patients with epilepsy. Epilepsia 1997; 38(11): 1255–1256. doi: 10.1111/j.1528-1157.1997.tb01226.x.
  17. Attilakos A, Fotis L, Dinopoulos A, et al. Antiphospholipid and antinuclear antibodies in children with idiopathic epilepsy: A 2-year prospective study. Journal of Clinical Neurology (Seoul, Korea) 2020; 16(1): 140–144. doi: 10.3988/jcn.2020.16.1.140.
  18. Bektaş Ö, Jacobson L, Tutkak H, et al. Epilepsy and autoimmunity in pediatric patients. Neuropediatrics 2015; 46(1): 013–019. doi: 10.1055/s-0034-1389895.
  19. Constantin T, Kálovics T, Ponyi A, et al. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Medical Science Monitor 2009; 15(4): CR164–169.
  20. Islam MA, Alam F, Cavestro C, et al. Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. Autoimmunity Reviews 2018; 17(8): 755–767. doi: 10.1016/j.autrev.2018.01.025.
  21. Hubbard JA, Hsu MS, Fiacco TA, et al. Glial cell changes in epilepsy: Overview of the clinical problem and therapeutic opportunities. Neurochemistry International 2013; 63(7): 638–651. doi: 10.1016/j.neuint.2013.01.017.
  22. Anders S, Breithausen B, Herde M, et al. Rapid astrocyte morphology changes support epileptic activity. Opera Medica et Physiologica 2017; 3(S1): 5–6.
  23. Murphy TR, Binder DK, Fiacco TA. Turning down the volume: Astrocyte volume change in the generation and termination of epileptic seizures. Neurobiology of Disease 2017; 104: 24–32. doi: 10.1016/j.nbd.2017.04.016.
  24. Caronti B, Calderaro C, Alessandri C, et al. Serum anti-β2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. Journal of Autoimmunity 1998; 11(5): 425–429. doi: 10.1006/jaut.1998.0214.
  25. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: Intrinsic immuneffector cell of the brain. Brain Research Reviews 1995; 20(3): 269–287. doi: 10.1016/0165-0173(94)00015-h.
  26. Bianchi MT, Song L, Zhang H, et al. Two different mechanisms of disinhibition produced by GABAA receptor mutations linked to epilepsy in humans. Journal of Neuroscience 2002; 22(13): 5321–5327. doi: 10.1523/JNEUROSCI.22-13-05321.2002.
  27. Brey R, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: A consensus report. Lupus 2011; 20(2): 153–157. doi: 10.1177/0961203310396748.
  28. Eyo UB, Murugan M, Wu LJ. Microglia–neuron communication in epilepsy. Glia 2017; 65(1): 5–18. doi: 10.1002/glia.23006.
  29. Uludag IF, Duksal T, Tiftikcioglu BI, et al. IL-1β, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure 2015; 26: 22–25. doi: 10.1016/j.seizure.2015.01.009.
  30. Ravizza T, Boer K, Redeker S, et al. The IL-1β system in epilepsy-associated malformations of cortical development. Neurobiology of Disease 2006; 24(1): 128–143. doi: 10.1016/j.nbd.2006.06.003.
  31. Hurst J, Prinz N, Lorenz M, et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1β and caspase-1 in monocytes and dendritic cells. Immunobiology 2009; 214(8): 683–691. doi: 10.1016/j.imbio.2008.12.003.
  32. Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 2017; 58(7): 1181–1189. doi: 10.1111/epi.13797.
  33. van den Munckhof B, de Vries EE, Braun KP, et al. Serum inflammatory mediators correlate with disease activity in electrical status epilepticus in sleep (ESES) syndrome. Epilepsia 2016; 57(2): e45–e50. doi: 10.1111/epi.13274.
  34. Lehtimäki KA, Liimatainen S, Peltola J, et al. The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy. Epilepsy Research 2011; 95(1–2): 184–187. doi: 10.1016/j.eplepsyres.2011.03.004.